Pooja Manroa is an Endocrinology/Metabolic physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 18 publications with 318 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
209 Fair Oaks Ave
South Pasadena, CA 910301814
Telephone
626-396-2900Provider last certified this registry record 9 Jun 2022.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20257 payments
- Abbott LaboratoriesProgram year20251 payment
- Dexcom, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
63.8%GLP-1 receptor agonist24.9%Ozempic73%Mounjaro27%Part D<11 patientsSGLT2 inhibitor11.8%Farxiga71%Jardiance29%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
19.5%l-Thyroxine15.8%Levothyroxine Sodium100%Part D≥33 patientsThyroid Hormone Synthesis Inhibitor3.8%Methimazole100%Part D<11 patientsCardiovascular
10.6%Statin8.2%Atorvastatin Calcium63%Rosuvastatin Calcium37%Part D<11 patientsAngiotensin receptor blocker (ARB)2.3%Losartan Potassium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SUN-798 Hypercalcemia of Malignancy: Hormonal Insights Across Cancer Types
Journal of the Endocrine Society
2025 - 8104 Rare Case Of Ectopic Cushing’s Syndrome Secondary To Metastatic Parotid Pleomorphic Adenocarcinoma
Journal of the Endocrine Society
2024 - THU282 Improved Fournier’s Gangrene Outcomes With Prior SGLT2i Or Metformin Usage
Journal of the Endocrine Society
2023 - Molecular alterations in Hürthle cell nodules and preoperative cancer risk
Endocrine Related Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Erminia Massarelli, MD
City Of Hope National Medical Center
Swetha Thiruvengadam, MD
City Of Hope National Medical Center
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”